1Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344:1383-1389.
2Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995, 333:1301-1307.
3Bonetti PO, Lerman LO, Napoli C, et al. Statin effects beyond lipid lowering-are they clinically relevant? Eur Heart J, 2003, 24:225-248.
4Indolfi C, Di Lorenzo E, Perrino C, et al. Hydroxy-methylglutaryl-conezyme A reductase inhibitior simvastatin prevents cardiac hypertrophy induced by pressure overload and inhibits p21ras activation. Circulation, 2002, 106:2118-2124.
5Masafumi T, Yukiyo O, Hitoaki O, et al. Fluvastatin enhance apoptosis in cytokine- stimulated vascular smooth muscle cells. J Cardiovasc Pharmacol, 2002, 39:310-317.
6Nickenig G, Baumer AT, Temur Y, et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholedterolemic men. Circulation, 1999, 100:2131-2134.
7Dechend R, Fiebeler A, Park JK, et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation, 2001, 104: 576-581.
8Luo JD, Zhang WW, Zhang GP, et al. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol, 1999, 26: 903-908.
9Wassmann S, Laufs U, Baumer AT, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: involvement of angiotensin AT1 receptor expression and Rac1 GTPase. Mol Pharmacol, 2001, 59:6
10Peterson JT, Hallak H, Johnson L, et al. Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation, 2001, 103:2303-2309.
